Literature DB >> 30689342

Dark Classics in Chemical Neuroscience: Δ9-Tetrahydrocannabinol.

Samuel D Banister1,2, Jonathon C Arnold1,3, Mark Connor4, Michelle Glass5, Iain S McGregor1,6.   

Abstract

Cannabis ( Cannabis sativa) is the most widely used illicit drug in the world, with an estimated 192 million users globally. The main psychoactive component of cannabis is (-)- trans-Δ9-tetrahydrocannabinol (Δ9-THC), a compound with a diverse range of pharmacological actions. The unique and distinctive intoxication caused by Δ9-THC primarily reflects partial agonist action at central cannabinoid type 1 (CB1) receptors. Δ9-THC is an approved therapeutic treatment for a range of conditions, including chronic pain, chemotherapy-induced nausea and vomiting, and multiple sclerosis, and is being investigated in indications such as anorexia nervosa, agitation in dementia, and Tourette's syndrome. It is available as a regulated pharmaceutical in products such as Marinol, Sativex, and Namisol as well as in an ever-increasing range of unregistered medicinal and recreational cannabis products. While cannabis is an ancient medicament, contemporary use is embroiled in legal, scientific, and social controversy, much of which relates to the potential hazards and benefits of Δ9-THC itself. Robust contemporary debate surrounds the therapeutic value of Δ9-THC in different diseases, its capacity to produce psychosis and cognitive impairment, and the addictive and "gateway" potential of the drug. This review will provide a profile of the chemistry, pharmacology, and therapeutic uses of Δ9-THC as well as the historical and societal import of this unique, distinctive, and ubiquitous psychoactive substance.

Entities:  

Keywords:  cannabidiol; cannabinoid; cannabis; chemistry; pharmacology; tetrahydrocannabinol

Mesh:

Substances:

Year:  2019        PMID: 30689342     DOI: 10.1021/acschemneuro.8b00651

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  13 in total

Review 1.  Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis.

Authors:  Graziella Filippini; Silvia Minozzi; Francesca Borrelli; Michela Cinquini; Kerry Dwan
Journal:  Cochrane Database Syst Rev       Date:  2022-05-05

2.  Orally administered cannabidiol does not produce false-positive tests for Δ9 -tetrahydrocannabinol on the Securetec DrugWipe® 5S or Dräger DrugTest® 5000.

Authors:  Danielle McCartney; Richard C Kevin; Anastasia S Suraev; Christopher Irwin; Ronald R Grunstein; Camilla M Hoyos; Iain S McGregor
Journal:  Drug Test Anal       Date:  2021-08-30       Impact factor: 3.234

3.  Structure-activity relationships for 5F-MDMB-PICA and its 5F-pentylindole analogs to induce cannabinoid-like effects in mice.

Authors:  Grant C Glatfelter; John S Partilla; Michael H Baumann
Journal:  Neuropsychopharmacology       Date:  2021-11-20       Impact factor: 8.294

4.  Acute Effects of Cannabis Concentrate on Motor Control and Speed: Smartphone-Based Mobile Assessment.

Authors:  Leah N Hitchcock; Brian L Tracy; Angela D Bryan; Kent E Hutchison; L Cinnamon Bidwell
Journal:  Front Psychiatry       Date:  2021-01-22       Impact factor: 4.157

5.  Defluorodearomatization: A Photocatalytic Birch-Like Reduction That Enables C-C Bond Formation and Provides Access to Unnatural Cannabinoids.

Authors:  Jon I Day; Sascha Grotjahn; Sameera Senaweera; Burkhard Koenig; Jimmie D Weaver Iii
Journal:  J Org Chem       Date:  2021-06-02       Impact factor: 4.354

6.  Cannabis constituents interact at the drug efflux pump BCRP to markedly increase plasma cannabidiolic acid concentrations.

Authors:  Lyndsey L Anderson; Maia G Etchart; Dilara Bahceci; Taliesin A Golembiewski; Jonathon C Arnold
Journal:  Sci Rep       Date:  2021-07-22       Impact factor: 4.379

7.  The Cannabis Constituent Cannabigerol Does Not Disrupt Fear Memory Processes or Stress-Induced Anxiety in Mice.

Authors:  Cilla Zhou; Neda Assareh; Jonathon C Arnold
Journal:  Cannabis Cannabinoid Res       Date:  2021-06-28

8.  Dual-Purpose Materials Based on Carbon Xerogel Microspheres (CXMs) for Delayed Release of Cannabidiol (CBD) and Subsequent Aflatoxin Removal.

Authors:  Farid B Cortés; Karol Zapata; Benjamín A Rojano; Francisco Carrasco-Marín; Jaime Gallego; M Alejandra Hernández; Camilo A Franco
Journal:  Molecules       Date:  2019-09-19       Impact factor: 4.411

Review 9.  A Critical Review of the Role of the Cannabinoid Compounds Δ9-Tetrahydrocannabinol (Δ9-THC) and Cannabidiol (CBD) and their Combination in Multiple Sclerosis Treatment.

Authors:  Éamon Jones; Styliani Vlachou
Journal:  Molecules       Date:  2020-10-25       Impact factor: 4.411

Review 10.  Prescribing medicinal cannabis.

Authors:  Jonathon C Arnold; Tamara Nation; Iain S McGregor
Journal:  Aust Prescr       Date:  2020-09-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.